Phase III clinical trials in platinum-sensitive patients have demonstrated its efficacy in ovarian and prostate cancers, or in combination with anti-angiogenic agents (VEGF inhibitors) in HER2-negative, BRCA1-mutant triple-negative breast cancers (TNBC), as well as in combination with Temozolomide in melanoma patients, are clear examples exhibiting adequate pharmacokinetics and clinically relevant antitumor activity. The gene discussed is VEGFA; the disease is prostate carcinoma.